Abstracts tagged "anti-TNF therapy"

Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Leslie R. Harrold^1,2, George W. Reed^1,2, Jennie Best³, Steve Zlotnick³, Gioia Persuitte² and Joel M. Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴The Albany Medical College, Albany, NY
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…
Abstract Number: 2592 • 2016 ACR/ARHP Annual Meeting
The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink
Samuel Hawley¹, René Cordtz², Lene Dreyer³, Christopher J. Edwards⁴, Nigel K Arden⁵, Antonella Delmestri⁵, Cyrus Cooper^1,6, Andrew Judge⁵ and Daniel Prieto-Alhambra⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ²Dept. of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁷Internal Medicine and Primary Care, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol i Gurina-Institut Català de la Salut; Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Barcelona, Spain
Background/Purpose: In several developed countries it has been observed that the incidence of orthopaedic surgery among rheumatoid arthritis (RA) patients has been in decline, despite…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 1674 • 2016 ACR/ARHP Annual Meeting
Do TNF Inhibitors Change the Progression of Sacroiliitis?
Deeba Minhas¹, MinJae Lee^2,3, Mohammad H. Rahbar³, Lianne S. Gensler⁴, John D. Reveille⁵ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Medicine, University of Texas Health Science Center at Houston, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac (SI) joints and spine causing structural changes seen on clinical radiography. Studies have…
Abstract Number: 2602 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Laurence Zitvogel⁷ and Xavier Mariette^8,9, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷IGR - INSERM U1015, Villejuif, France, ⁸Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁹INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 618 • 2016 ACR/ARHP Annual Meeting
Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry
Philip Baer¹, Andrew Chow², Michael Starr³, Boulos Haraoui⁴, Regan Arendse⁵, Michelle Teo⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Allen J Lehman⁹, Francois Nantel¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova⁹, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methods: Results: After 6 months of treatment, 46% of patients had achieved treatment target of remission or low DA, and 54% were…
Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 2617 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Vibeke Strand¹, Namita Tundia², Yan Song³, Dendy Macaulay⁴ and Mahesh Fuldeore⁵, ¹School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Analysis Group, Inc., New York, NY, ⁵AbbVie, Inc, North Chicago, IL
Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This…
Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting
Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Philip Mease¹, Manish Mittal², Martha Skup², Matthew Davis³, Arijit Ganguli², Scott Johnson³ and Michael Schiff⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴University of Colorado, Greenwood Village, CO
Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
Abstract Number: 619 • 2016 ACR/ARHP Annual Meeting
Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Philip Baer¹, Mary Bell², Boulos Haraoui³, Louis Bessette⁴, John Kelsall⁵, Maqbool Sheriff⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova¹⁰, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that, when sustained good clinical response has been achieved with a biologic therapy, traditional disease-modifying anti-rheumatic drugs (DMARDs) and other…
Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Christopher T. Ritchlin⁴, Doquyen H. Huynh³, Renganayaki Pandurengan², Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
Abstract Number: 2626 • 2016 ACR/ARHP Annual Meeting
Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis
Line Dam Heftdal^1,2, Kristian Stengaard-Pedersen², Merete Lund Hetland^3,4, Kim Hørslev-Petersen⁵, Peter Junker⁶, Mikkel Østergaard^4,7, Malene Hvid^8,9, Bent Deleuran^2,8,9, Holger Jon Møller^8,10 and Stinne Greisen^2,9, ¹Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, Copenhagen, Denmark, ⁵King Christian X's Hospital for Rheumatic Diseases,, University of Southern Denmark, Graasten, Denmark, ⁶Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ¹⁰Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints and infiltration by activated macrophages. TNFa is a central…
Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Omer Karadag¹, Ediz Dalkilic², Ahmet Mesut Onat³, Orhan Kucuksahin⁴, Timucin Kasifoglu⁵, Bunyamin Kisacik⁶, Omer Nuri Pamuk⁷, Neslihan Yilmaz⁸, Suleyman Serdar Koca⁹, Veli Yazisiz¹⁰, Pinar Talu Ocakci¹¹, Mehmet Sayarlioglu¹², Ender Terzioglu¹³, Sukran Erten^14,15, Mustafa Ferhat Oksuz¹⁶ and Umut Kalyoncu¹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁶Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁷Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁸Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁹Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, ¹⁰Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹¹Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, ¹²Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ¹³Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁴Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, ¹⁵Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁶Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…

« Previous Page
1
…
7
8
9
10
11
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].